BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 18, Issue 8
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (7707)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.
Item 
Count 
PDF951
HTML6247
Figures (1-4)253
Tables (1-3)256
 Sum=7707
Feb 28, 2012 (publication date) through Jan 8, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777 [PMID: 22371636 DOI: 10.3748/wjg.v18.i8.767]
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/767.htm
Number Citing Articles
1
R. Ennaifer, N. Elleuch, M. Cheikh, H. Romdhane, H. Ben Nejma, N. Bel Hadj. La rifaximine : une nouvelle alternative dans la prévention des infections bactériennes chez le cirrhotique ?. Journal Africain d'Hépato-Gastroentérologie 2015; 9(3): 122 doi: 10.1007/s12157-015-0606-8
2
Rebeca Nevado, Raquel Forcén, Elena Layunta, María Divina Murillo, Laura Grasa. Neomycin and bacitracin reduce the intestinal permeability in mice and increase the expression of some tight-junction proteins. Revista Española de Enfermedades Digestivas 2015; 107 doi: 10.17235/reed.2015.3868/2015
3
Hiroshi Fukui, Hidetsugu Saito, Yoshiyuki Ueno, Hirofumi Uto, Katsutoshi Obara, Isao Sakaida, Akitaka Shibuya, Masataka Seike, Sumiko Nagoshi, Makoto Segawa, Hirohito Tsubouchi, Hisataka Moriwaki, Akinobu Kato, Etsuko Hashimoto, Kojiro Michitaka, Toshikazu Murawaki, Kentaro Sugano, Mamoru Watanabe, Tooru Shimosegawa. Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology 2016; 51(7): 629 doi: 10.1007/s00535-016-1216-y
4
Greg Padmore, Chad G. Ball. Textbook of Emergency General Surgery. 2023; : 389 doi: 10.1007/978-3-031-22599-4_25
5
Xianghui Han, Zhanyang Luo, Wenyi Wang, Peiyong Zheng, Tian Li, Zubing Mei, Jianyi Wang. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.696065
6
Ming Bai, Zhiping Yang, Xingshun Qi, Daiming Fan, Guohong Han. l‐ornithine‐l‐aspartate for hepatic encephalopathy in patients with cirrhosis: A meta‐analysis of randomized controlled trials. Journal of Gastroenterology and Hepatology 2013; 28(5): 783 doi: 10.1111/jgh.12142
7
Nina Kimer, Aleksander Krag, Flemming Bendtsen, Søren Møller, Lise Lotte Gluud. Rifaximin for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews 2015;  doi: 10.1002/14651858.CD011585
8
Kosuke Kaji, Norihisa Nishimura, Kei Moriya, Hitoshi Yoshiji. Clinical Investigation of Portal Hypertension. 2019; : 533 doi: 10.1007/978-981-10-7425-7_55
9
Philipp Lutz, Hans Dieter Nischalke, Christian P Strassburg, Ulrich Spengler. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World Journal of Hepatology 2015; 7(3): 304-314 doi: 10.4254/wjh.v7.i3.304
10
Mohammadreza Naderian, Heshmatollah Akbari, Morteza Saeedi, Amir Ali Sohrabpour. olyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East Journal of Digestive Diseases 2017; 9(1): 12 doi: 10.15171/mejdd.2016.46
11
Olivier Braissant, Valérie A. McLin, Cristina Cudalbu. Ammonia toxicity to the brain. Journal of Inherited Metabolic Disease 2013; 36(4): 595 doi: 10.1007/s10545-012-9546-2
12
Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, Chuan-Yong Guo. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/236963
13
José M. Ferro, Pedro Viana, Patrícia Santos. Management of Neurologic Manifestations in Patients with Liver Disease. Current Treatment Options in Neurology 2016; 18(8) doi: 10.1007/s11940-016-0419-0
14
Stephen M. Riordan. Liver Diseases. 2020; : 695 doi: 10.1007/978-3-030-24432-3_64
15
RIFAXIMIN. Gastroenterology Nursing 2013; 36(2): 140 doi: 10.1097/SGA.0b013e31828a02a0
16
Mitsuhiko Shibasaki, Takeshi Hatanaka, Yasushi Shimada, Tamon Nagashima, Masashi Namikawa, Shuichi Saito, Kenichi Hosonuma, Atsushi Naganuma, Daichi Takizawa, Hirotaka Arai, Takashi Kosone, Hitoshi Takagi, Ken Sato, Satoru Kakizaki, Toshio Uraoka. Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy. Kanzo 2020; 61(1): 1 doi: 10.2957/kanzo.61.1
17
Fiona Chautant, Maeva Guillaume, Marie-Angèle Robic, Jean-François Cadranel, Jean-Marie Peron, Hortensia Lison, Charlène Cool, Christophe Bureau, Véronique Duhalde. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World Journal of Hepatology 2020; 12(1): 10-20 doi: 10.4254/wjh.v12.i1.10
18
Sudhir Maharshi, Barjesh Chander Sharma, Siddharth Srivastava, Amit Jindal. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. Gut 2015; 64(8): 1341 doi: 10.1136/gutjnl-2014-308521
19
Reena Rajasuriar, Gabriela Khoury, Adeeba Kamarulzaman, Martyn A. French, Paul U. Cameron, Sharon R. Lewin. Persistent immune activation in chronic HIV infection. AIDS 2013; 27(8): 1199 doi: 10.1097/QAD.0b013e32835ecb8b
20
Jamir Pitton Rissardo, Sara Muhammad, Venkatesh Yatakarla, Nilofar Murtaza Vora, Paras Paras, Ana Letícia Fornari Caprara. Flapping Tremor: Unraveling Asterixis—A Narrative Review. Medicina 2024; 60(3): 362 doi: 10.3390/medicina60030362
21
Harry D Zacharias, Fady Kamel, Jaclyn Tan, Nina Kimer, Lise Lotte Gluud, Marsha Y Morgan. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD011585.pub2
22
David Holt. Small Animal Critical Care Medicine. 2015; : 458 doi: 10.1016/B978-1-4557-0306-7.00088-X
23
Motoh Iwasa, Yoshiyuki Takei. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia. Hepatology Research 2015; 45(12): 1155 doi: 10.1111/hepr.12495
24
Kashif Mohd Siddiqui, Sumeet Attri, Massimo Orlando, Filippo Lelli, Valeria Maida, Dominique Damais-Thabut, Soe Thiha Maung. Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis. GastroHep 2022; 2022: 1 doi: 10.1155/2022/1298703
25
Guihua Fang, Shuna Liu, Bin Liu. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03184-0
26
K. N. Woodward. Toxicological Effects of Veterinary Medicinal Products in Humans. 2012; : 273 doi: 10.1039/9781849735483-00273
27
Jian Fu, Yi Gao, Li Shi, Peter Starkel. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. PLOS ONE 2022; 17(4): e0267647 doi: 10.1371/journal.pone.0267647
28
Eamonn M.M. Quigley, Catherine Stanton, Eileen F. Murphy. The gut microbiota and the liver. Pathophysiological and clinical implications. Journal of Hepatology 2013; 58(5): 1020 doi: 10.1016/j.jhep.2012.11.023
29
C. García Huerta, J. Donate Ortega, A.B. Agarrabeitia Casado, R.M. Martín Mateos. Encefalopatía hepática. Medicine - Programa de Formación Médica Continuada Acreditado 2024; 14(10): 568 doi: 10.1016/j.med.2024.05.013
30
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020; 85(1): 56 doi: 10.1016/j.rgmxen.2019.09.003
31
Christopher F. Rose, Piero Amodio, Jasmohan S. Bajaj, Radha Krishan Dhiman, Sara Montagnese, Simon D. Taylor-Robinson, Hendrik Vilstrup, Rajiv Jalan. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology 2020; 73(6): 1526 doi: 10.1016/j.jhep.2020.07.013
32
E. Roeb, M. Roderfeld. Mikrobiom zwischen Intestinum und Leber. Der Gastroenterologe 2015; 10(2): 111 doi: 10.1007/s11377-014-0961-9
33
Stephen M. Riordan, Roger Williams. Neurocritical Care. 2019; : 370 doi: 10.1017/9781107587908.030
34
Praveen Sharma, Barjesh C. Sharma. Management of Overt Hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology 2015; 5: S82 doi: 10.1016/j.jceh.2014.04.004
35
P. Lutz, M. Parcina, I. Bekeredjian-Ding, A. Hoerauf, C. P. Strassburg, U. Spengler. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin. Infection 2014; 42(1): 175 doi: 10.1007/s15010-013-0449-4
36
Liz Toapanta-Yanchapaxi, Jorge A. López-Velázquez, Misael Uribe, Nahum Méndez-Sánchez. Minimal hepatic encephalopathy. Should we treat it?. Annals of Hepatology 2013; 12(3): 487 doi: 10.1016/S1665-2681(19)31013-0
37
Juan Cordoba. Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. ISRN Hepatology 2014; 2014: 1 doi: 10.1155/2014/236268
38
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035
39
C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepática. Revista de Gastroenterología de México 2020; 85(1): 56 doi: 10.1016/j.rgmx.2019.09.001
40
Use of Oral Antibiotics in Elderly Gastrointestinal Patients. Journal of the Korean Geriatrics Society 2012; 16(3): 108 doi: 10.4235/jkgs.2012.16.3.108
41
Praveen Sharma, Barjesh Chander Sharma. Disaccharides in the treatment of hepatic encephalopathy. Metabolic Brain Disease 2013; 28(2): 313 doi: 10.1007/s11011-013-9392-4
42
Donna M. Zucker, Rhoda Redulla. Lactulose Management of Minimal Hepatic Encephalopathy. Gastroenterology Nursing 2019; 42(1): 84 doi: 10.1097/SGA.0000000000000429
43
Khaled Amer, Mohamed S. Hashim, Eman Abd El Sameea, Manar Obada, Mostafa G. El Helbawy, Ahmed Edrees, Tary A. Salman, Omkolsoum Al Haddad, Mohsen Salama. Evaluation of rifaximin in Egyptian patients with hepatic encephalopathy. Egyptian Liver Journal 2013; 3(4): 113 doi: 10.1097/01.ELX.0000433599.23047.b1
44
Roberto Lorenzetti, Cosimo Prantera. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation 2013; 3(12): 1187 doi: 10.4155/cli.13.96
45
Sahaj Rathi, Radha K. Dhiman. Hepatobiliary Quiz (Answers)—14 (2015). Journal of Clinical and Experimental Hepatology 2015; 5(2): 175 doi: 10.1016/j.jceh.2015.06.007
46
Adam P. Buckholz, Robert S. Brown. Future Therapies of Hepatic Encephalopathy. Clinics in Liver Disease 2024; 28(2): 331 doi: 10.1016/j.cld.2024.02.002
47
Kristina R. Chacko, Samuel H. Sigal. Update on Management of Patients With Overt Hepatic Encephalopathy. Hospital Practice 2013; 41(3): 48 doi: 10.3810/hp.2013.08.1068
48
Philipp Lutz, Marijo Parcina, Isabelle Bekeredjian-Ding, Hans Dieter Nischalke, Jacob Nattermann, Tilman Sauerbruch, Achim Hoerauf, Christian P. Strassburg, Ulrich Spengler, Golo Ahlenstiel. Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites. PLoS ONE 2014; 9(4): e93909 doi: 10.1371/journal.pone.0093909
49
Paulina Vidal-Cevallos, Norberto C. Chávez-Tapia, Misael Uribe. Current approaches to hepatic encephalopathy. Annals of Hepatology 2022; 27(6): 100757 doi: 10.1016/j.aohep.2022.100757
50
Elliot B. Tapper, Z. Gordon Jiang, Vilas R. Patwardhan. Refining the Ammonia Hypothesis. Mayo Clinic Proceedings 2015; 90(5): 646 doi: 10.1016/j.mayocp.2015.03.003
51
M. Yu. Nadinskaia, M. V. Maevskaya, I. G. Bakulin, E. N. Bessonova, A. O. Bueverov, M. S. Zharkova, S. V. Okovityi, A. S. Ostrovskaya, K. A. Gulyaeva, V. T. Ivashkin. Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement). Russian Journal of Gastroenterology, Hepatology, Coloproctology 2024; 34(1): 85 doi: 10.22416/1382-4376-2024-34-1-85-100
52
Lewis W. Teperman. Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation Outcomes. International Journal of Hepatology 2013; 2013: 1 doi: 10.1155/2013/952828
53
Andrea Mancini, Francesca Campagna, Piero Amodio, Kieran M. Tuohy. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food & Function 2018; 9(3): 1373 doi: 10.1039/C7FO01528C
54
Ariadna Ramírez-Polo, Ernesto Márquez-Guillén, Adrián J. González-Aguirre, Iván E. Casanova-Sánchez, Rafael Chávez-Ruiz, Eduardo Carrillo-Maravilla, Eric López-Méndez. Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer device. Annals of Hepatology 2014; 13(4): 456 doi: 10.1016/S1665-2681(19)30854-3
55
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal, S K Sarin. A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. American Journal of Gastroenterology 2013; 108(9): 1458 doi: 10.1038/ajg.2013.219
56
N. Kimer, A. Krag, S. Møller, F. Bendtsen, L. L. Gluud. Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2014; 40(2): 123 doi: 10.1111/apt.12803
57
Federica Di Vincenzo, Alberto Nicoletti, Marcantonio Negri, Federica Vitale, Lorenzo Zileri Dal Verme, Antonio Gasbarrini, Francesca Romana Ponziani, Lucia Cerrito. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics 2023; 12(6): 1068 doi: 10.3390/antibiotics12061068
58
G.‐Q. Zhu, K.‐Q. Shi, S. Huang, L.‐R. Wang, Y.‐Q. Lin, G.‐Q. Huang, Y.‐P. Chen, M. Braddock, M.‐H. Zheng. Systematic review with network meta‐analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2015; 41(7): 624 doi: 10.1111/apt.13122
59
Malcolm M. Wells, Thomas D. Schiano. Liver Disorders. 2017; : 99 doi: 10.1007/978-3-319-30103-7_8
60
Lu Lu, Chao Wu, Bing-jie Lu, Dong Xie, Zheng Wang, Nisma Lena Bahaji Azami, Yong-tong An, Hui-jun Wang, Guan Ye, Ming-yu Sun. BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats. Journal of Ethnopharmacology 2020; 249: 112301 doi: 10.1016/j.jep.2019.112301
61
Anna-Lena Laguna de la Vera, Christoph Welsch, Waltraud Pfeilschifter, Jonel Trebicka. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes. 2021; : 159 doi: 10.1016/B978-0-12-821927-0.00004-8
62
Michael S. Bleszynski, Alexsander K. Bressan, Emilie Joos, S. Morad Hameed, Chad G. Ball. Acute care and emergency general surgery in patients with chronic liver disease: how can we optimize perioperative care? A review of the literature. World Journal of Emergency Surgery 2018; 13(1) doi: 10.1186/s13017-018-0194-1
63
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345